Table 1.
Baseline demographics and disease characteristics of 394 patients with and without complete virological response at week 78 (univariate analysis).
| Variables | Total n=394 |
Persistent viremia n=90 |
Complete virological response n=304 | P-value* |
|---|---|---|---|---|
| Age (years) ≤30y, n (%) | 77 (19.5) | 27 (30.0) | 50 (16.4) | 0.004 |
| Male gender, n (%) | 294 (74.6) | 69 (76.7) | 225 (74.0) | 0.611 |
| BMI ≥25 kg/m2, n (%) | 134 (34.0) | 32 (35.6) | 102 (33.6) | 0.725 |
| PLT (×109/L) | 155.0 (121.0-194.0) | 155.0(127.3-199.0) | 155.0 (118.3-193.8) | 0.609 |
| ALT ≤ 40 IU/ml, n (%) | 123 (31.2) | 24 (26.7) | 99 (32.6) | 0.289 |
| ALT ≤ 30 IU/ml for male and ≤ 19 IU/ml for female, n (%) |
47 (11.9) | 8 (8.9) | 39 (12.8) | 0.311 |
| Albumin ≥35 g/L, n (%) | 373 (94.7) | 88 (97.8) | 285 (93.8) | 0.135 |
| TBIL ≤ 17.1 μmol/L, n (%) | 245 (62.2) | 53 (58.9) | 192 (63.2) | 0.463 |
| TC ≤ 5.18 mmol/L, n (%) | 332 (84.3) | 71 (78.9) | 261 (85.9) | 0.111 |
| TG ≤ 1.69 mmol/L, n (%) | 351 (89.1) | 81 (90.0) | 270 (88.8) | 0.752 |
| Cr ≤ 106 IU/ml for male and ≤ 97 IU/ml for female, n (%) |
387 (98.2) | 88 (97.8) | 299 (98.4) | 0.661 |
| FPG ≥7.0 mmol/L, n(%) | 11 (2.8) | 1 (1.1) | 10 (3.3) | 0.461 |
| HBV DNA ≥8 log10IU/mL, n(%) | 43 (10.9) | 25 (27.8) | 18 (5.9) | <0.0001 |
| HBsAg ≥4 log10 IU/mL, n(%) | 53 (13.5%) | 27 (30.0) | 26 (8.6) | <0.0001 |
| HBeAg positive, n (%) | 226 (57.4%) | 73 (81.1) | 153(50.3) | <0.0001 |
| qAnti-HBc<3log10IU/mL), n(%) | 49 (12.4%) | 22 (24.4) | 27 (8.9) | <0.0001 |
| FIB-4 | 1.5 (1.0-2.3) | 1.4 (0.9-2.3) | 1.6 (1.0-2.4) | 0.329 |
| <1.45, n(%) | 166 (42.1) | 44 (48.9) | 122 (40.1) | |
| 1.45-3.25, n(%) | 191 (48.5) | 39 (43.3) | 152 (50.0) | |
| >3.25, n(%) | 37 (9.4) | 7 (7.8) | 30 (9.9) | |
| APRI | 0.7 (0.4-1.3) | 0.9 (0.4-1.4) | 0.7 (0.4-1.3) | 0.636 |
| ≤0.5, n(%) | 105 (26.6) | 23 (25.6) | 82 (27.0) | |
| 0.5-1.5, n(%) | 186 (47.2) | 40 (44.4) | 146 (48.0) | |
| >1.5, n(%) | 103 (26.1) | 27 (30.0) | 76 (25.0) | |
| LSM (kPa) | 11.7 (8.1-17.6) | 12.2 (8.6-19.0) | 11.5 (7.8-17.2) | 0.774 |
| <7.4, n(%) | 76 (19.3) | 15 (17.4) | 61 (20.1) | |
| 7.4-9, n(%) | 57 (14.5) | 12 (13.0) | 45 (14.8) | |
| 9-12, n(%) | 78 (19.8) | 17 (17.8) | 61 (20.1) | |
| ≥12, n(%) | 183 (46.4) | 46 (41.8) | 137 (45.1) | |
| HAI ≥5, n(%) | 285 (72.3) | 70 (77.8) | 215 (70.7) | 0.189 |
| Fibrosis stages >3, n(%) | 211 (53.6) | 39 (43.3) | 172 (56.6) | 0.027 |
| HAI ≥5 or F≥3, n(%) | 365 (92.6) | 82 (91.1) | 283 (93.1) | 0.527 |
| Patients with family history of HCC, n(%) | 48 (12.2) | 14 (15.6) | 34 (11.2) | 0.270 |
| Patients with family history of hepatitis B, n(%) | 188 (47.7) | 46 (51.1) | 142 (47.0) | 0.495 |
P value: comparision between patients with with and without complete virological response at week 78. %, percentage, range from 0-100%。
BMI, body mass index; ALT, Alanine transaminase; TBil, total bilirubin; CR, creatinine; FPG, fasting plasma glucose; PLT, platelet counts; TC total cholesterol; TG triglyceride; AFP, alpha fetoprotein; LSM, liver stiffness measurement; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; Anti-HBc, hepatitis B core antibody; HAI, histology activity index; ULN upper limit of normal; FIB-4, fibrosis-4; APRI, AST to platelet ratio index. The meaning of the bold values is to highlight statistically significant indicators.